Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.39 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (enterocytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0660
Sealed predictions
- CREB3L3 in dopamine neurons, braak-0.34 (p 0.373) → +0.27 (p 0.474)receipt 0667
Swarm cases
receipt 0667: CREB3L3 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.709, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.709, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.09 (p 0.709, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to +0.01, sign flips 2; without severely affected donors -0.09 (p 0.709, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CREB3L3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts